🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,328 results for “China” Clear

  1. Olverembatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

    phase 2 small molecule completed

    1 trial

  2. Olverembatinib+INO

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HSCT

    phase 2 small molecule active

    1 trial

  3. Open Mini-Laparotomy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hydrocephalus

    phase 2 other active

    1 trial

  4. Oral levetiracetam

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Neonatal Seizures

    phase 2 small molecule terminated

    1 trial

  5. Orelabrutinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  6. PBSC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stem Cell Transplantation, Hematopoietic

    phase 2 mab active

    1 trial

  7. PBSC transplantation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cirrhosis

    phase 2 other active

    1 trial

  8. PD-1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Cancer Patients

    phase 2 small molecule active

    1 trial

  9. PD-1 inhbitor+SHR0302

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. PEX168 or placebo

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type 2 Diabetes

    phase 2 small molecule completed

    1 trial

  11. PG2

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Stroke

    phase 2 small molecule completed

    1 trial

  12. PI3K inhibitor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoma, T-Cell

    phase 2 small molecule active

    1 trial

  13. PIK3CA inhibitor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Neoplasm

    phase 2 small molecule active

    1 trial

  14. PM8002

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. Pancreatoduodenectomy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 other active

    1 trial

  16. Pectin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Slow Transit Constipation

    phase 2 small molecule active

    1 trial

  17. Pembrolizumab 200 mg IV infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stage IIIB(N2) Non-small Cell Lung Cancer

    phase 2 mab active

    1 trial

  18. Pemetrexe

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  19. Prednisone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Langerhans Cell Histiocytosis of Bone

    phase 2 small molecule active

    1 trial

  20. QAMS-containing PMMA

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Oral Health

    phase 2 other completed

    1 trial

  21. QL1706

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Platinum-resistant Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  22. Qinbudan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pulmonary Tuberculosis

    phase 2 small molecule completed

    1 trial

  23. Qingying oral liquid and modified Da Huang-Huang Lian Xiexin mouthwash

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Radiation-induced Oral Mucositis

    phase 2 small molecule active

    1 trial

  24. Qishen Granules

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Heart Failure

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources